By blocking the interaction of PD-L1 and PD-1 to prevent immune evasion of tumors, anti-PD-L1 therapy with monoclonal antibodies such as avelumab has been proven effective for cancers like Merkel cell carcinoma and non-small cell lung cancer [17, 18]. Here, CD274 is linked to cancer.